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Aims: It is unknown whether cardiomyocyte hypertrophy and the transition to fatty acid 25 
oxidation as the main source of energy after birth is dependent on the maturation of the 26 
cardiomyocytes’ metabolic system, or on the limitation of substrate availability before birth. 27 
This study aimed to investigate whether intrafetal administration of a PPARγ agonist, 28 
rosiglitazone, during late gestation can stimulate the expression of factors regulating cardiac 29 
growth and metabolism in preparation for birth, and the consequences on cardiac contractility 30 
in the fetal sheep at ~140d gestation.  31 
 32 
Methods: The mRNA expression and protein abundance of key factors regulating growth 33 
and metabolism were quantified using qRT-PCR and Western blotting, respectively. Cardiac 34 
contractility was determined by measuring the Ca2+ sensitivity and maximum Ca2+ activated 35 
force of skinned cardiomyocyte bundles.  36 
 37 
Results: Rosiglitazone treated fetuses had a lower cardiac abundance of insulin signaling 38 
molecules, including IRβ, IRS-1, phospho-IRS-1(Tyr895), PI3K regulatory subunit p85, 39 
PI3K catalytic subunit p110α, phospho-PDPK-1(Ser241), Akt-1, phospho-Akt(ser273), 40 
PKCζ, phospho-PKC(Thr410), AS160, phospho-AS160(Thr642) and GLUT-4. Additionally, 41 
cardiac abundance of regulators of fatty acid β-oxidation, including AdipoR1, AMPKα, 42 
phospho-AMPKα(Thr172), phospho-ACC(Ser79), CPT-1 and PGC-1α was lower in the 43 
rosiglitazone treated group. Rosiglitazone administration also resulted in a decrease in 44 
cardiomyocyte size. 45 
 46 
Conclusions: Rosiglitazone administration in the late gestation sheep fetus resulted in a 47 
decreased abundance of factors regulating cardiac glucose uptake, fatty acid β-oxidation and 48 
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cardiomyocyte size. These findings suggest that activation of PPARγ using rosiglitazone does 49 
not promote the maturation of cardiomyocyte, rather, it may decrease cardiac metabolism and 50 
compromise cardiac health later in life.  51 
  52 
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ACC  Acetyl CoA Carboxylase 57 
AdipoR1 Adiponectin Receptor 1 58 
Akt  Protein Kinase B 59 
AMPK  AMP-Activated Protein Kinase 60 
ANP  Atrial Natriuretic Peptide 61 
AS160  Akt substrate 160kDa 62 
BCA  Bicinchoninic Acid 63 
CDK-4 Cyclin Dependent Kinase 4 64 
CPT-1  Carnitine Palmitoyltransferase-1 65 
FAT/CD36 Fatty Acid Translocase 66 
FATP1 Fatty Acid Transport Protein 1 67 
GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase 68 
GLUT-1 Glucose Transporter type-1 69 
GLUT-4 Glucose Transporter type-4 70 
HPRT1 Hypoxanthine Phosphoribosyltransferase 1 71 
IGF  Insulin-like Growth Factor 72 
IGF-1R Insulin-like Growth Factor 1 Receptor 73 
IGF-2R Insulin-like Growth Factor 2 Receptor 74 
IR  Insulin Receptor 75 
IRS-1  Insulin Receptor Substrate-1  76 
PDH  Pyruvate Dehydrogenase 77 
PDK-4  Pyruvate Dehydrogenase Kinase-4 78 
PDPK-1 3-Phosphoinositide-dependent Protein Kinase 1 79 
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PGC1α PPARγ-coactivator 1 alpha  80 
PGK1  Phosphoglycerate Kinase 1 81 
PI3K  Phosphatidylinositol 3-Kinase 82 
PKCζ  atypical Protein Kinase C zeta 83 
PPARα Peroxisome Proliferator Activated Receptor alpha 84 
PPARγ Peroxisome Proliferator Activated Receptor gamma  85 
PVDF  Polyvinylidene Difluoride 86 
qRT-PCR quantitative Real Time Reverse Transcription-PCR 87 






Early growth of the heart is associated with proliferation of mononucleated cardiomyocytes. 92 
In mid gestation, these mononucleated cells become binucleated cardiomyocytes, which 93 
contribute to increasing cardiac mass by hypertrophy (5, 17). In the human and sheep, the 94 
endowment of cardiomyocytes present in the adult heart is largely determined before birth 95 
(42). In the fetal heart, lactate and glucose areis the main sources of energy, while after birth, 96 
there is a switch to fatty acid β-oxidation (9, 21). It is not known whether the dominance of 97 
glucose as the main fuel source in the fetal cardiomyocyte is a consequence of the relatively 98 
limited availability of fatty acids in the fetal circulation or rather as a consequence of the 99 
immaturity of key enzyme systems present within the fetal cardiomyocyte. It is also unclear 100 
whether the maturation of cardiomyocytes is linked to cardiac metabolism, however several 101 
factors are known to impact on cardiac maturation and metabolism. For example, 102 
glucocorticoids are essential in the maturation of key fetal organ systems, including the lung, 103 
gut and heart in late gestation (10). In rats, glucocorticoid infusion increases the abundance of 104 
the transcription factor Peroxisome Proliferator Activated Receptor gamma (PPARγ)  leading 105 
to increased ATP production (26). Additionally, PPARγ may regulate cardiac insulin 106 
signalling, as it has been shown that cardiac specific PPARγ knockout mice  have decreased 107 
phosphorylation of Protein kinase B (Akt), which is a key insulin signalling molecule (8). 108 
Rosiglitazone, a PPARγ agonist, increases plasma adiponectin concentration, which is a key 109 
regulator of cardiac fatty acid β-oxidation (1). Rosiglitazone also upregulates  adiponectin 110 
mRNA expression in perirenal fat in sheep (29) and increases cardiac adiponectin and 111 
Adiponectin Receptor 1 (AdipoR1) in cultured cardiomyocytes from adult rats and mice (7, 112 
41). Furthermore, rosiglitazone administration in adult rats induces cardiac hypertrophy (8). 113 
Thus one possibility is that an upregulation of PPARγ in late gestation may induce changes in 114 
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factors that regulate insulin dependent cardiac glucose uptake, fatty acid β-oxidation and 115 
cardiac hypertrophy in fetal cardiomyocytes in preparation for the transition to extrauterine 116 
life.  117 
 118 
Cardiac glucose uptake in the fetus is maintained through the activity of the insulin 119 
independent Glucose Transporter type-1 (GLUT-1) (13). In postnatal life, however, cardiac 120 
glucose uptake is regulated by the insulin dependent (GLUT-4), through the activation of the 121 
Insulin Receptor (IR), Insulin Receptor Substrate-1 (IRS-1), Phosphatidylinositol 3-Kinase 122 
(PI3K), 3-Phosphoinositide-dependent Protein Kinase 1 (PDPK-1) and/or Akt. Activation of 123 
PDPK-1 results in the phosphorylation and activation of the atypical Protein Kinase C zeta 124 
(PKCζ), while phosphorylation of Akt results in the phosphorylation and activation of the 125 
Akt substrate 160kDa (AS160). Phosphorylated PKCζ and AS160 each play a major role in 126 
the translocation of the GLUT-4 to the plasma membrane to facilitate glucose uptake (38).  127 
 128 
Cardiac fatty acid uptake is facilitated by Fatty Acid Translocase (FAT/CD36) and Fatty 129 
Acid Transport Protein 1 (FATP1) (36). Fatty acid oxidation, however, is regulated by the 130 
activation of AdipoR1 by adiponectin binding, leading to the phosphorylation, and hence 131 
activation of AMP-Activated Protein Kinase (AMPK), which in turn phosphorylates Acetyl 132 
CoA Carboxylase (ACC) resulting in its inhibition (32, 34). ACC catalyses the production of 133 
malonyl CoA, which inhibits the action of Carnitine Palmitoyltransferase-1 (CPT-1) in 134 
facilitating fatty acid transport into the mitochondria (20). Fatty acid β-oxidation in the heart 135 
is also regulated by PGC1α and PPAR alpha (PPARα), which stimulate mitochondrial 136 
biogenesis and fatty acid β-oxidation by increasing the transcription of regulators such as 137 
CPT-1 (39). Pyruvate Dehydrogenase Kinase-4 (PDK-4) also plays a role in promoting 138 
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cardiac fatty acid β-oxidation by inhibiting glucose oxidation through inhibition of the 139 
Pyruvate Dehydrogenase complex (PDH) (37). 140 
  141 
Insulin-like Growth Factor-1 (IGF-1) and IGF-2, which act through the IGF-1 receptor (IGF-142 
1R), play an important role in cell growth and metabolism through activation of downstream 143 
signalling pathways (6). IGF-2 receptor (IGF-2R) is a clearance receptor, function to degrade 144 
IGF-2, therefore limiting its action on IGF-1R in normally grown fetuses (18). However, 145 
recent studies have shown that activation of IGF-2R signalling leads to pathological cardiac 146 
hypertrophy during late gestation in the sheep fetus (40), indicated by increased expression of 147 
the marker of hypertrophy,  Atrial Natriuretic Peptide (ANP) (30). Additionally, IGF-1 also 148 
regulates proliferation through the activation of the Cyclin Dependent Kinase 4 (CDK-4) and 149 
Cyclin D1 complex, which is inhibited by the CDK inhibitor, p27 (24). The expression of 150 
CDK-4 is stimulated by the transcription factor c-myc (15).  151 
 152 
We hypothesise that activation of PPARγ with intrafetal rosiglitazone infusion will stimulate 153 
cardiac insulin dependent glucose uptake and fatty acid β-oxidation, thus stimulating cardiac 154 
maturation and growth. In this study, we have therefore determined the effect of PPARγ 155 
activation using rosiglitazone infusion to the sheep fetus for ~16 days in late gestation on the 156 
mRNA expression and protein abundance of factors regulating cardiac glucose uptake, fatty 157 
acid β-oxidation, cardiomyocyte proliferation and hypertrophy, as well as cardiomyocyte 158 
parameters in late gestation at ~140d gestation. We have also determined both Ca2+ sensitivity 159 
and maximum Ca2+ -activated force in small bundles of chemically skinned cardiac muscle, 160 




Materials and methods 163 
 164 
Animals, surgery and rosiglitazone administration 165 
All procedures were approved by the Institute for Medical and Veterinary Science Animal 166 
Ethics Committee.  167 
 168 
Pregnancies were confirmed in 14 adult Merino ewes by ultrasound scanning in early 169 
gestation. Surgery was performed between 123 and 126d gestation using aseptic techniques. 170 
General anesthesia was induced by intravenous injection of sodium thiopentone (1.25g, 171 
Pentothal; Rhone Merieux, Pinkenba, Qld, Australia) and maintained with 1.5-2.5% 172 
isoflurane (Fluothane; ICI, Melbourne, Vic, Australia) in oxygen.  173 
 174 
Ethanol was diluted in water to make a sterile 15% ethanol (vol/vol) solution. Rosiglitazone 175 
(30 mg, generously donated by GlaxoSmithKline, Brentford, UK) was dissolved in sterile 176 
15% ethanol (15 mg/ml) and then injected into a 2-ml Alzet osmotic pump (DURECT Corp., 177 
Cupertino, CA) under sterile conditions. Rosiglitazone was administered directly to the fetus 178 
with Alzet osmotic pumps, which were inserted subcutaneously over the scapula at surgery as 179 
previously described (29). Fetuses assigned to the control group (vehicle) also had Alzet 180 
osmotic pumps inserted containing 15% ethanol. The solution was released from the osmotic 181 
pumps at an average rate of 60μl/d for both rosiglitazone and control groups, according to the 182 
manufacturer’s specifications regarding the estimated flow rate of the pumps (DURECT 183 
Corp., Cupertino, CA). Based on this flow rate, and the amount of drug initially loaded into 184 
each pump,  This this regimen delivered aprovided an estimated dose of ~3.6mg/fetus/day of 185 
rosiglitazone. This resulted in  (calculated according to the amount of rosiglitazone loaded 186 
into the pumps and flow rate of the pumps), resulting in a plasma concentration of ~25ng/ml, 187 
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across  or 7.14ng/ml/kg (25ng/ml divided by average fetal sheep weight of 3.5kg) (3). This 188 
plasma concentration is comparable to those seen in adults treated with an oral dose of 189 
8mg/day, which results in a plasma concentration of ~598ng/ml or 7.97ng/ml/kg (598ng/ml 190 
divided by average adult weight of 75kg) (9) the infusion period and was sufficient to 191 
activate PPARγa target genes in adipose tissue, liver and skeletal muscle. Further, we have 192 
reported previously that this regime resulted in accumulation of rosiglitazone in the fetus 193 
throughout the infusion period (3). 194 
 195 
Blood sampling, post mortem and tissue collection 196 
Fetal arterial blood (0.5 ml) was collected daily from the time of surgery to post mortem for 197 
determination of fetal blood gases PO2 and PCO2 using an ABL 520 analyzer (Radiometer, 198 
Copenhagen, Denmark) (29). 199 
 200 
Between 137 and 140d gestation, ewes were humanely killed with an overdose of sodium 201 
pentobarbitone (Virbac Pty Ltd., Peakhurst, NSW, Australia). Timing of tissue collection was 202 
determined to allow rosiglitazone infusion for 16 ± 1d. Singleton and twin fetuses from the 203 
control (n=12) and rosiglitazone treated (n=9) groups were delivered by hysterectomy and 204 
weighed. All organs were dissected and weighed, and samples of heart muscle (left ventricle) 205 
were snap frozen in liquid nitrogen and stored at −80C. The remainder of the heart was 206 
perfused through the aorta with heparin and saturated potassium chloride, to prevent blood 207 
clotting and to arrest the heart in diastole. Cardiomyocytes were enzymatically isolated from 208 
the heart as previously described (27) and fixed in 1% paraformaldehyde (Table 1) and stored 209 
until determination of the percentage of mononucleated cardiomyocytes and cardiomyocyte 210 
size. 211 
 212 




Quantitative real-time RT-PCR (qRT-PCR) 213 
RNA was extracted from ~50mg of left ventricle tissue using Trizol reagent (Invitrogen) 214 
(Table 1). RNA was purified using the RNeasy Mini Kit (QIAGEN). cDNA was synthesised 215 
using the purified RNA and Superscript 3 reverse transcriptase (Invitrogen) with random 216 
hexamers. The expression of mRNA transcripts of glucose transporters (GLUT-1 and GLUT-217 
4), cardiac lipid metabolism factors (Adiponectin, AdipoR1, AdipoR2, CD36, FATP, 218 
PPARα, PGC1α and PDK-4), cardiac growth factors (IGF-1, IGF-2, IGF-1R and IGF-2R), 219 
proliferative factors (p27, Cyclin D1, CDK-4 and c-myc), cardiac hypertrophy markers 220 
(ANP) and the housekeeper genes Hypoxanthine Phosphoribosyltransferase 1 (HPRT1), 221 
Phosphoglycerate Kinase 1 (PGK1) and Glyceraldehyde-3-Phosphate Dehydrogenase 222 
(GAPDH) (33) was measured by quantitative Real Time Reverse Transcription-PCR (qRT-223 
PCR) using the Sybr Green system in an ABI Prism 7500 Sequence Detection System 224 
(Applied Biosystems, Foster City, CA, USA). Normalised expression of the target genes was 225 
calculated using DataAssist Software v3.0 (Applied Biosystems) (14). 226 
 227 
Primer sequences were validated for use in sheep in this (Table 2) or in prior studies (23, 28, 228 
29). Each amplicon was sequenced to ensure the authenticity of the DNA product and a 229 
dissociation melt curve analysis was performed after each run to demonstrate amplicon 230 
homogeneity. Each qRT-PCR reaction well contained: 5l Sybr Green Master Mix (Applied 231 
Biosystems), 2l primer (forward and reverse), 2l molecular grade H2O and 1l of cDNA 232 
(50ng/μl). The cycling conditions consisted of 40 cycles of 95C for 15min and 60C for 233 
1min.  234 
 235 
Quantification of protein abundance 236 
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The protein abundance of factors regulating cardiomyocyte proliferation and hypertrophy, 237 
glucose and fatty acid metabolism and cardiac contractility were determined using Western 238 
Blotting (31). Briefly, left ventricle samples (~50mg) (Table 1) were sonicated in 800μl lysis 239 
buffer (50mM Tris HCL pH 8.0, 150mM NaCl, 1% NP-40, 1mM Na3VO4, 30mM NaF, 240 
10mM Na4P2O7, 10mM EDTA, 1 protease inhibitor tablet) and centrifuged at 12,000g at 4
oC 241 
for 15min to remove insoluble material. Protein content of the clarified extracts was 242 
quantified using micro Bicinchoninic Acid (microBCA) protein assay. Prior to Western Blot 243 
analysis, samples (10μg protein) were subjected to SDS-PAGE and stained with Coomassie 244 
blue reagent (Thermo Fisher Scientific, Rockford, IL, USA) to ensure equal loading of the 245 
proteins.  Equal volumes and concentrations of protein were subjected to SDS-PAGE. The 246 
proteins were transferred onto a PolyScreen® Polyvinylidene Difluoride (PVDF) 247 
hybridization transfer membrane (PerkinElmer, Waltham, MA, USA) using a semi-dry 248 
blotter (Hoefer Inc, Holliston, CA, USA). The membranes were blocked with 5% BSA in 249 
Tris-Buffered Saline with 1% Tween-20 (TBS-T) at room temperature for 1h  and then 250 
incubated overnight with primary antibody against IRβ, PKCζ, GLUT-1, PPARα, CPT-1 251 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); IGF-1R, phospho-IRS-1 (Tyr895), 252 
p110α, Akt1, Akt2, total phospho-Akt (Ser473), PDPK-1, phospho-PDPK1 (Ser241), 253 
phospho-PKCζ (Thr410), AS160, phospho-AS160 (Thr642), total AMPK, total phospho-254 
AMPK (Thr172), PGC1α, ACC, phospho-ACC (Ser79) (Cell Signalling, Danvers, MA, 255 
USA); IRS-1, p85 (Merck Milipore, Billerica, MA, USA); AdipoR1 (Epitomics, Burlingame, 256 
CA, USA); GLUT-4, PDK-4, ANP (Abcam, Cambridge, UK) and IGF-2R (BD Transduction 257 
laboratories, San Jose, CA, USA). Membranes were washed and bound antibody detected 258 
using anti-rabbit or anti-mouse (Cell Signalling) horseradish peroxidase-conjugated 259 
secondary IgG antibodies at room temperature for 1h. Enhanced chemiluminescence reagents 260 
SuperSignal® West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) and 261 
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ImageQuantTM LAS 4000 (GE Healthcare, Rydalmere, NSW, Australia) was used to detect 262 
the protein:antibody complexes. AlphaEaseFC (Alpha Innotech Corporation, Santa Clara, 263 
CA, USA) was utilised to quantify the optical density of the specific bands of the target 264 
proteins (40). 265 
 266 
Determination of proportion of mononucleated cardiomyocytes and cardiomyocyte size  267 
Cardiomyocytes were stained with methylene blue (ProSiTech, Thuringowa, Qld, Australia) 268 
and examined using an Olympus VANOX-T microscope (Olympus Optical Co. Ltd, Tokyo, 269 
Japan). The relative proportion of mononucleated and binucleated cardiomyocytes was 270 
determined by counting a total of 300 cardiomyocytes. To determine cardiomyocyte size, the 271 
length and width of 50 mononucleated and 50 binucleated cardiomyocytes were assessed 272 
using AnalySIS software (Software Imaging System, Gulfview Heights, SA, Australia) (40).  273 
 274 
Cardiac contractility studies 275 
 276 
Bundle isolation: Under a dissecting microscope, small bundles of cardiomyocytes (Table 1) 277 
of ~300 m diameter were isolated from the left ventricle and then attached between a force 278 
transducer (AE801 Memscap, Skoppun, Norway) and stationary pin with fine suture silk. The 279 
bundle was then briefly immersed in a high-EGTA physiological solution (solution 1; see 280 
below). We have shown in a previous study that stretching bundles by 130% of the resting 281 
length resulted in the production of optimum force to Ca2+ activation consistent with the 282 
approach of other studies (35).  In this study, the bundle was therefore stretched by 120% of 283 
its slack length to produced ~90% of optimum maximum Ca2+-activated force. Bundles were 284 
then chemically skinned in solution 1 containing 2% Triton X-100 for 30min (35) (see 285 
below). The output of the transducer was acquired and digitized by a PowerLab/8Sp 286 
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(ADInstruments, Castle Hill, NSW, Australia) data-acquisition system and the subsequent 287 
force responses recorded onto both a paper chart recorder (Kipp Zonnen, Bohemia, NY, 288 
USA) and computer using PowerLab Chart v4.1 computer software (ADInstruments). 289 
 290 
Force-calcium relationship:  The standard composition of the skinned fibre solutions used 291 
were (mM): (a) Solution 1 - Hepes, 90; EGTA, 50; total Mg2+, 10.3; total ATP, 8; creatine 292 
phosphate (CP), 10; (b) Solution 2 - Hepes, 90; EGTA, 50; total Ca2+, 48.5; total Mg2+, 8.12; 293 
total ATP, 8; CP, 10; (c) Solution 3 - Hepes, 90; EGTA, 0.05; HDTA2- (1,6-diaminohexane-294 
N,N,N_,N_-tetraacetic acid), 50; total Mg2+, 8.6; total ATP, 8; CP, 10. All solutions contained 295 
(mM): K+, 126; Na+, 36; azide, 1; free Mg2+, 1 and the pH and osmolality were 7.10  0.01 296 
and 295 mmols kg-1, respectively. 297 
 298 
All bundles were chemically skinned in solution 1 containing 2% Triton-X 100 for 30min. 299 
This procedure destroys all membranes, leaving only the contractile apparatus intact. Skinned 300 
bundles were then washed in fresh solution 1 for 5min and then equilibrated in a weakly 301 
buffered (2 mM) EGTA solution by combining proportions of solutions 1 and 3. The force-302 
pCa relationship was then determined by activating each bundle in solutions of increasing 303 
free Ca2+, created by combining solutions 1 and 2 in various ratios (pCa = log10[Ca
2+]; 7.3 to 304 
5.5); the precise pCa in each activation ratio was subsequently measured by using an Orion 305 
Ca2+-sensitive electrode. Bundles were maximally activated by exposure to solution 2 (pCa 306 
~4.5). The maximum Ca2+-activated force responses in bundles were normalized to the cross-307 
sectional area of the bundle (mN/mm2) for comparison. Cross-sectional area was determined 308 
by the equation area r2, assuming the muscle bundle had a cylindrical form and taking the 309 
average diameter across the fiber bundle. Submaximal force relative to the maximum Ca2+-310 
activated force was used in determination of the force-pCa relationship. For each fiber 311 
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bundle, the relative force produced for each free [Ca2+] was plotted by use of GraphPad Prism 312 
v4.01 (GraphPad Software, San Diego, CA, USA) and a sigmoidal dose-response curve (Hill 313 
equation: Y=min + (max - min)/(1 + 10((LogEC50 - X) x n))) was fitted. Parameters Max (pCa 4.5) 314 
and Min (pCa 7.0) of the fitted curve were set to 100 and 0%, respectively. From each 315 
resulting curve the pCa required to produce 50% (pCa50) of maximum Ca
2+-activated force 316 
and the Hill coefficient (n) were measured and averaged as reported in previous studies (35). 317 
 318 
Statistical Analyses 319 
All data are presented as mean  SEM. Two-way ANOVA was performed using the 320 
Statistical Package for the Social Sciences Software (SPSS Inc, Chicago, IL, USA), and 321 
showed no effect of fetal number, thus data from singletons and twins were combined and 322 
Student’s unpaired t-tests was used to determine the effects of rosiglitazone compared to 323 
controls on cardiac mRNA expression and protein abundance and to compare contractility 324 




There was no effect of rosiglitazone administration on fetal weight at ~140d gestation 329 
(control, 4.65±0.15kg; rosiglitazone, 4.83±0.17kg). There was also no effect of rosiglitazone 330 
administration on mean fetal arterial PO2 (control, 22.5±0.6mmHg; rosiglitazone, 331 
21.5±1.0mmHg) and PCO2 (control, 49.9±0.7mmHg; rosiglitazone, 49.5±0.5mmHg) in late 332 
gestation. 333 
 334 
Impact of rosiglitazone on the mRNA expression and protein abundance of factors 335 
regulating cardiac glucose uptake in late gestation 336 
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Rosiglitazone administration during late gestation decreased the cardiac protein abundance of 337 
IRβ (P<0.05), IRS-1 (P<0.05), phospho-IRS-1 (Tyr895) (P<0.05), PI3K (p85) (P<0.05), 338 
PI3K (p110α) (P<0.05) , phospho-PDPK-1 (Ser241) (P<0.05), Akt1 (P<0.05), phospho-Akt 339 
(Ser273) (P<0.001), PKCζ (P<0.05), phospho-PKCζ (Thr410) (P<0.01), AS160 (P<0.05), 340 
phospho-AS160 (Thr642) (P<0.05) and GLUT-4 (P<0.01) (Table 3). The cardiac abundance 341 
of GLUT-1, however, was increased (P<0.05) in rosiglitazone treated fetuses compared to 342 
controls (Table3). The protein abundance of PDPK-1 (Table 3) and mRNA expression of 343 
GLUT-1 and GLUT-4 were not different in rosiglitazone treated fetuses compared to controls 344 
(Table 3). 345 
 346 
Impact of rosiglitazone on the mRNA expression and protein abundance of factors 347 
regulating cardiac fatty acid β-oxidation in late gestation 348 
The cardiac protein abundance of AdipoR1 (P<0.01), AMPK (P<0.05), phospho-AMPK 349 
(Thr172) (P<0.05), ACC (P<0.01), phospho-ACC (Ser79) (P<0.05), CPT-1 (P<0.05), PDK-4 350 
(P<0.05) and PGC-1α (P<0.05) (Table 4) was decreased in rosiglitazone treated fetuses 351 
compared to controls. There were no differences, however, in the mRNA expression of 352 
cardiac PPARγ, adiponectin, AdipoR1, AdipoR2, CD36, FATP1, PPARα and PGC1α 353 
between groups (Table 4). 354 
 355 
Impact of rosiglitazone on the mRNA expression and protein abundance of factors 356 
regulating cardiac proliferation and hypertrophy and cardiac parameters in late 357 
gestation 358 
There was no effect of rosiglitazone on the mRNA expression of cardiac IGF-1, IGF-2, IGF-359 
1R, IGF-2R, c-myc, CDK-4, Cyclin D1, p27 and ANP (Table 5). There was also no 360 
difference in the protein abundance of IGF-1R, IGF-2R and ANP in the rosiglitazone treated 361 
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fetuses compared to controls (Table 5). There was, however, a decrease in the absolute length 362 
of the mononucleated (P<0.05) and binucleated (P<0.05) cardiomyocytes (Table 6). The 363 
absolute and relative heart weight and absolute width of the mononucleated and binucleated 364 
cardiomyocytes, as well as the percentage of mononucleated cardiomyocytes were not 365 
changed in rosiglitazone treated fetuses compared to controls (Table 6). 366 
 367 
Impact of rosiglitazone on cardiac contractility parameters in late gestation 368 
There was no difference in the Ca2+ sensitivity of the contractile apparatus (Figure 1) and 369 
maximum Ca2+-activated force between control and rosiglitazone groups (Table 7). 370 
 371 
Discussion 372 
In this study, we aimed to determine whether activation of PPARγ with intrafetal 373 
rosiglitazone infusion could stimulate cardiac insulin dependent glucose uptake and fatty acid 374 
β-oxidation. Interestingly, we have shown that rosiglitazone administration during late 375 
gestation resulted in decreased protein abundance of key insulin signalling molecules (Figure 376 
2), which may lead to a decrease in cardiac glucose uptake in postnatal life.  This finding is in 377 
contrast to the known effect of rosiglitazone in improving whole body insulin sensitivity and 378 
glucose uptake in the heart and skeletal muscle in adult humans and mice with type 2 diabetes 379 
(12, 19, 25). In addition, rosiglitazone treated fetuses also had a decrease in the protein 380 
abundance of key regulators of cardiac fatty acid β-oxidation,  (Figure 3), which may have a 381 
detrimental effect in postnatal life, as the cardiomyocytes are more reliant on fatty acid β-382 
oxidation to produce energy. This finding is in contrast to studies in adults in human, rats and 383 
mice, whereby rosiglitazone increased cardiac adiponectin and AdipoR1 expression (1, 7, 384 
41). However, rosiglitazone resulted in similar decrease in the mRNA expression of AdipoR1 385 
and protein abundance of GLUT-4 and phospho-AMPK (Thr172) in diabetic rats treated with 386 
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3mg/kg/day of rosiglitazone compared to untreated diabetic rats (11). Our findings showed 387 
that rosiglitazone administration in late gestation fetuses resulted in a different effect than in 388 
adults, but similar to when administered to adult diabetic rats. Furthermore, iIt is interesting 389 
that we found a decrease in the abundance of the insulin signalling and fatty acid β-oxidation 390 
molecules in this study despite no change in the maternal and fetal glucose and free fatty acid 391 
concentration in this cohort of animals, shown in the previous study (29). . We have 392 
previously shown that intrafetal infusion of rosiglitazone resulted in decreased plasma insulin 393 
concentrations in late gestation (29), and it is therefore possible that this resulted in the 394 
observed decrease in the abundance of the insulin signalling factors. We speculate that the 395 
decrease in the abundance of the cardiac regulators of fatty acid β-oxidation may be a 396 
consequence of limited availability  of fatty acids in utero and/or as a negative response to the 397 
increased adiponectin expression in the fetal perirenal adipose tissue, which is the main 398 
source of plasma adiponectin (29). We have previously shown that intrafetal infusion of 399 
rosiglitazone resulted in decreased plasma insulin concentration (29), and this may lead to the 400 
observed decrease in the abundance of the insulin signalling factors.  401 
 402 
We have also shown that rosiglitazone administration did not change the Ca2+ sensitivity of 403 
the contractile apparatus and maximum Ca2+-activated force. There was, however, increased 404 
cardiac GLUT-1 protein abundance in rosiglitazone treated fetuses. This finding shows that 405 
the decrease in the abundance of insulin signalling and fatty acid β-oxidation molecules may 406 
not affect cardiac function in late gestation fetuses, which is consistent with the knowledge 407 
that fetal cardiomyocytes are dependent on glycolysis (21) from glucose uptake facilitated by 408 
GLUT-1. Interestingly, rosiglitazone treated fetuses had reduced absolute mononucleated and 409 
binucleated cardiomyocyte length, in the absence of any differences in absolute or relative 410 
heart weight. This finding is in contrast to a study in adult rats administered with 411 
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rosiglitazone, which resulted in cardiac hypertrophy (8), but consistent with reports of the 412 
antihypertrophic effect of PPARγ in PPARγ knockout mice (22). Furthermore, rosiglitazone 413 
and pioglitazone interact with numerous ‘off-target’ proteins involved in lipid and glucose 414 
metabolism (16). Additionally, administration of  thiazolidinediones (TZDs) in adult mice 415 
limits cardiac lipid accumulation following a high fat diet, but with a decrease in PPARγ 416 
expression and other factors regulating cardiac fatty acid β-oxidation (2). This finding leads 417 
the authors to speculate that TZDs may exert this effect through a cardiac PPARγ 418 
independent mechanism. Findings from this and other studies (2, 16) and the opposing effect 419 
between the impact of rosiglitazone administration and PPARγ knockout on hypertrophy in 420 
adult rats and mice (8, 22), therefore raise the possibility that the effect of rosiglitazone on 421 
cardiomyocyte growth and metabolism may be a consequence of indirect binding or the ‘off 422 
target’ effects of rosiglitazone. Furthermore, these findings raise concerns regarding the 423 
specificity of TZDs such as rosiglitazone as PPARγ ‘specific’ agonist. 424 
 425 
In addition, a decrease in cardiomyocyte length in the absence of a reduction in absolute or 426 
relative heart weight may suggest an increase in the number of cardiomyocytes in the heart. 427 
This hypothesis is consistent with the increase in GLUT-1 abundance, which may result in 428 
increased substrate availability for glycolysis, which is the major source of energy for 429 
proliferating cardiomyocytes (21). However, we were not able to measure cardiomyocyte 430 
number in this cohort because the tissue was not collected appropriately for non-biased 431 
assessment of this parameter (4). Another limitation of this study is the gender bias in theWe 432 
also cannot exclude the possibility that there were differences in the cardiac response to 433 
rosiglitazone exposure between males and females, and as such the small differences in the 434 
relative number of males and females between the protein quantification assay (controls and 435 
rosiglitazone treated groups used in) protein quantification assay and the contractility assays 436 
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(Ca2+ activated force; rosiglitazone treated group), which is male dominateneeds to be 437 
considered when interpreting the results. d. Therefore, iIt is possible, therefore, that the 438 
decrease in the abundance of the insulin signalling and fatty acid β-oxidation molecules 439 
found in this study is only applicable for males and the lack of change in the contractility 440 
(Ca2+ activated force) study may be due to the male dominance in the rosiglitazone treated 441 
group. Furthermore, it is worth noting that there was a variation of 3 days in the timinge 442 
during gestational age at which of when the rosiglitazone was administeredexposure 443 
commenced. It is possible that this. This disparity may have an effect on theimpacted on the 444 
response of the cardiomyoctes to magnitude of the rosiglitazone treatment, as the 445 
cardiomyocytes are rapidly maturing during late gestation since the period of rosiglitazone 446 
exposure may have coincided with subtly different stages in their development (5, 17). 447 
Although, we have previously shown that there was no difference in the percentage of 448 
mononucleated cardiomyocytes between 132-134d and 137-141d gestation (27). Therefore, 449 
this disparity in the timing of rosiglitazone administration may cause a variation within the 450 
data sets, however it is unlikely to alter the findings in this study. 451 
 452 
Perspective and significance 453 
Rosiglitazone administration during late gestation resulted in decreased abundance of cardiac 454 
insulin signalling molecules and regulators of fatty acid β-oxidation, as well as a decrease in 455 
cardiomyocyte size, with no effect on measures of cardiac contractility. These findings 456 
suggest that stimulation of PPARγ using rosiglitazone in late gestation is not adequate to 457 
stimulate cardiac insulin-dependent glucose uptake and fatty acid β-oxidation, but it may 458 
result in adverse effects for cardiac health in later life. However, it is important to note that 459 
findings from this and other studies (2, 8, 16, 22) also suggest that rosiglitazone and other 460 
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TZDs may not specifically act as PPARγ agonists, and that the potential adverse 461 
cardiometabolic effects may not necessarily due to the activation of cardiac PPARγ. 462 
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Figure captions 600 
 601 
Figure 1. Representative traces of the force-pCa relationship from chemically skinned 602 
bundles of fetal cardiomyocytes from the left ventricles of control () and rosiglitazone 603 
treated () animals.  The pCa and Hill coefficients respectively for control fetuses were 6.19 604 
and 1.80 and for rosiglitazone treated fetuses were 6.24 and 1.31. 605 
 606 
Figure 2. Summary diagram of the impact of rosiglitazone administration on protein 607 
abundance of factors regulating cardiac glucose uptake in late gestation sheep fetus. 608 
 609 
Figure 3. Summary diagram of the impact of rosiglitazone administration on protein 610 
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Table 2. Primer sequences for qRT-PCR. 615 
Gene name Sequence Accession no. 
HPRT1 F: 5' GCTGAGGATTTGGAGAAGGTGT 3' NM_001034035.1 
 
R: 5' GGCCACCCATCTCCTTCAT 3' 
 
PGK1 F: 5' ACTCCTTGCAGCCAGTTGCT 3’ NM_001034299 
 
R: 5' AGCACAAGCCTTCTCCACTTCT 3' 
 
GAPDH F: 5' CCTGGAGAAACCTGCCAAGT 3' DQ152956.1 
 
R: 5' GCCAAATTCATTGTCGTACCA 3' 
 
p27 F: 5' AAACCCAGAGGACACGCATTTGGT 3' NM_001100346.1 
 
R: 5' TTTGAGGAGAGGAATCATCTGCGG 3' 
 
Cyclin D1 F: 5' GCCGAGAAGCTGTGCATTTAC 3' NM_001046273.1 
 
R: 5' CCAGGACCAGCTCCATGTG 3' 
 
CDK-4 F: 5' AGGCTTGCCAGTGGAGACCATAAA 3' NM_001037594.1 
 
R: 5' GGTGAACGATGCAGTTGGCATGAA 3' 
 
c-myc F: 5' CTACAGATGCCCACAATCTGCACT 3' NM_001174109.1 
 
R: 5' TGGTATGGTTTCATCTGGGAAGGC 3' 
 
ANP F: 5' ATCACCACGAGCTTCCTCCTCTTT 3' NM_001160027.1 
 
R: 5' ATACTTGTGAGGGCACAGCCTCAT 3' 
 
AdipoR1 F: 5' ACACTCCCTGGGCAATAAACTCCA 3' BC102259 
 
R: 5’ TTCTGAAGTCCCAGTCCATCGCTT 3’ 
 
AdipoR2 F: 5' TCTCATGGCTGTTCCACACAGTCT 3' BC110019 
 
R: 5' AGCAAGGTTGCGGGTTACAGTAGA 3' 
 
CD36 F: 5' TGGTGTGCTAGACATTGGCAAATG 3' BC103112.1 
 
R: 5' TGTTGACCTGCAGCCGTTTTGC 3' 
 
FATP1 F: 5' AGCCTGGTCAAGTTCTGTTCTGGA 3' NM_001033625.2 
 
R: 5' AGAAGAGTCGATCATCCATGCCCT 3' 
 
PDK-4 F: 5' GCACCAACGCCTGTGATGGATAAT 3' NM_001101883.1 
 





Table 3. Impact of rosiglitazone on the mRNA expression and protein abundance of 617 
factors regulating glucose uptake in heart muscle in late gestation. 618 
Gene expression (MNE) Control Rosiglitazone 
GLUT-1 0.050 ± 0.002 0.051 ± 0.006 
GLUT-4 0.14 ± 0.02 0.13 ± 0.01 
   
Protein abundance (Au x 102)   
IRβ 848 ± 91 572 ± 44* 
IRS-1 384 ± 63 239 ± 23* 
phospho-IRS-1 (Tyr895) 1018 ± 57 860 ± 88* 
PI3K (p85) 199 ± 9 158 ± 11* 
PI3K (p110α) 456 ± 9 355 ± 32* 
PDPK-1 628 ± 93 475 ± 65 
phospho-PDPK-1 (Ser241) 301 ± 29 207 ± 23* 
Akt1 253 ± 25 169 ± 21* 
phospho-Akt (Ser273) 1818 ± 228 234 ± 55*** 
PKCζ 1004 ± 101 696 ± 72* 
phospho-PKCζ (Thr410) 952 ± 106 337 ± 71** 
AS160 216 ± 38 105 ± 19* 
phospho-AS160 (Thr642) 253 ± 9 76 ± 30** 
GLUT-4 245 ± 17 185 ± 18* 
GLUT-1 50 ± 8 76 ± 6 * 
Data presented as mean ± standard error of mean. MNE, mean normalised expression; Au, 619 
arbitrary units. * P<0.05, ** P<0.01, *** P<0.001. Immunoblots of proteins with altered 620 
abundance shown in Supporting Figure.621 
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Table 4. Impact of rosiglitazone on the mRNA expression and protein abundance of 622 
factors regulating lipid metabolism in heart muscle in late gestation. 623 
Gene expression (MNE) Control Rosiglitazone 
PPARγ 0.016 ± 0.003 0.015 ± 0.002 
Adiponectin 0.005 ± 0.001 0.004  ± 0.001 
AdipoR1 0.32 ± 0.10 0.20 ± 0.02 
AdipoR2 1.40 ± 0.51 0.75 ± 0.13 
CD36 4.52 ± 0.46 4.32 ± 0.46 
FATP1 0.13 ± 0.02 0.13 ± 0.02 
PPARα 0.22 ± 0.06 0.18 ± 0.03 
PGC1α 0.81 ± 0.19 0.63 ± 0.06 
   
Protein abundance (Au x 102)   
AdipoR1 477 ± 89 191 ± 16** 
AMPK 570 ± 35 445 ± 31* 
phospho-AMPK (Thr172) 432 ± 88 193 ± 42* 
ACC 279 ± 31 172 ± 16** 
phospho-ACC (Ser79) 310 ± 54 193 ± 23* 
CPT-1 99 ± 12 59 ± 10* 
PDK-4 157 ± 38 66 ± 13* 
PGC1α 304 ± 45 112 ± 41* 
Data presented as mean ± standard error of mean. MNE, mean normalised expression; Au, 624 
arbitrary units. * P<0.05, ** P<0.01. Immunoblots of proteins with altered abundance shown 625 




Table 5. Impact of rosiglitazone on the mRNA expression and protein abundance of 628 
factors regulating proliferation and hypertrophy, and markers of hypertrophy in heart 629 
muscle in late gestation. 630 
Gene expression (MNE) Control Rosiglitazone 
IGF-1 0.12 ± 0.01 0.09 ± 0.02 
IGF-2 12.0 ± 1.4 13.3 ± 1.6 
IGF-1R 0.58 ± 0.05 0.57 ± 0.04 
IGF-2R 1.8 ± 0.1 1.8 ± 0.2 
p27 0.31 ± 0.06 0.30 ± 0.02 
Cyclin D1 0.021 ± 0.003 0.018 ± 0.003 
CDK-4 0.18 ± 0.04 0.16 ± 0.03 
c-myc 0.23 ± 0.03 0.23 ± 0.03 
ANP 0.32 ± 0.09 0.27 ± 0.07 
   
Protein abundance (Au x 102)    
IGF-1R 540 ± 74 377 ± 48 
IGF-2R 529 ± 14 565 ± 76 
ANP 167 ± 18 161 ± 10 
Data presented as mean ± standard error of mean. MNE, mean normalised expression; Au, 631 





Table 6. Impact of rosiglitazone on heart and cardiomyocyte growth in heart muscle in 635 
late gestation. 636 
Heart and cardiomyocyte measures Control Rosiglitazone 
Absolute heart weight (g/kg) 32.9 ± 1.4 34.0 ± 1.9 
Relative heart weight (g/kg) 7.1 ± 0.3 6.9 ± 0.2 
Percentage of mononucleated cardiomyocytes (%) 50.5 ± 1.4 54.1± 4.0 
Mononucleated cardiomyocyte length (mm) 60.3 ± 1.7 53.2 ± 1.0* 
Mononucleated cardiomyocyte width (mm) 10.0 ± 0.6 10.8 ± 0.4 
Binucleated cardiomyocyte length (mm) 77.7 ± 2.3 68.0 ± 1.2* 
Binucleatedcardiomyocyte width (mm) 10.8 ± 0.6 11.6 ± 0.4 




Table 7. Impact of rosiglitazone on the contractile apparatus of small bundles of fetal 639 
sheep heart tissue. 640 




Control 6.07 ± 08 1.92 ± 0.17 7.10 ± 1.57 
Rosiglitazone 6.12 ± 0.1 1.50 ± 0.14 5.60 ± 0.90 
Data presented as mean ± standard error of mean.  641 
 642 
